In neuronal plasma membrane, two syntaxin isoforms, HPC-1/syntaxin 1A (STX1A) and syntaxin 1B (STX1B), are predominantly expressed as soluble N-ethylmaleimide-sensitive fusion attachment protein receptors, also known as t-SNAREs. We previously reported that glutamatergic and GABAergic synaptic transmissions are impaired in Stx1b null mutant (Stx1b À/À ) mice but are almost normal in Stx1a null mutant (Stx1a À/À ) mice. These observations suggested that STX1A and STX1B have distinct functions in fast synaptic transmission in the central nervous system (CNS). Interestingly, recent studies indicated that Stx1a À/À or Stx1a +/À mice exhibit disruption in the monoaminergic system in the CNS, causing unusual behaviour that is similar to neuropsychological alterations observed in psychiatric patients. Here, we studied whether STX1B contributes to the regulation of monoaminergic system and if STX1B is related to neuropsychological properties in human neuropsychological disorders similar to STX1A. We found that monoamine release in vitro was normal in Stx1b +/À mice unlike Stx1a À/À or Stx1a +/À mice, but the basal extracellular dopamine (DA) concentration in the ventral striatum was increased. DA secretion in the ventral striatum is regulated by GABAergic neurons, and Stx1b +/À mice exhibited reduced GABA release both in vitro and in vivo, disrupting the DAergic system in the CNS of these mice. We also found that Stx1b +/À mice exhibited reduced pre-pulse inhibition (PPI), which is believed to represent one of the prominent schizotypal behavioural profiles of human psychiatric patients. The reduction in PPI was rescued by DA receptor antagonists. These observations indicated that STX1B contributes to excess activity of the DAergic system through regulation of GABAergic transmission.
Introduction
Neurotransmitter release is regulated by the soluble N-ethylmaleimide-sensitive fusion attachment protein receptor (also known as SNARE) complex, which is composed of syntaxin1, SNAP25 and VAMP2 (Rizo & S€ udhof, 2012) . In neurons, two syntaxin1 isoforms, HPC-1/syntaxin 1A (STX1A) and syntaxin 1B (STX1B), which are transcribed from different genes, are predominantly expressed (Bennett et al., 1992; Inoue et al., 1992) . Both STX1A and STX1B are located on the axonal plasma membrane and regulate vesicle exocytosis at presynaptic terminals. These two proteins are highly homologous, and both proteins are normally co-expressed in most neurons in the central nervous system (CNS), but only Stx1a is present in endocrine cells (Ruiz-Montase et al., 1996; Ohara-Imaizumi et al., 2007) . Therefore, STX1A and STX1B likely have similar functions in neurons. Previously, we generated mutant mice lacking Stx1a (Fujiwara et al., 2006) or Stx1b Mishima et al., 2014) . Stx1a null mutant (Stx1a À/À ) mice develop normally, and glutamatergic and GABAergic fast synaptic transmission in vitro is almost normal; however, monoamine release and neuropeptide release in vitro and in vivo are reduced (Fujiwara et al., 2011 (Fujiwara et al., , 2016 Mishima et al., 2012) . In contrast, Stx1b null mutant (Stx1b À/À ) mice die within 2 weeks after birth, and glutamatergic and GABAergic fast synaptic transmissions in vitro are seriously impaired . These observations indicated that STX1A and STX1B have distinct functions in fast synaptic transmission in the CNS. Several studies have suggested an association between synaptic dysfunction and pathogenesis of human neuropsychological disorders (Johnson et al., 2008; Ramos-Miguel et al., 2015) . Disruption of the monoaminergic system may be related to unusual neuropsychological properties (Di Giovanni et al., 2016) . In particular, recent reports demonstrated that the expression of STX1A mRNA is disrupted in patients with autism spectrum disorder (Nakamura et al., 2011) , and that a significant correlation is present between a single nucleotide polymorphism in STX1A and attention deficit hyperactivity disorder (Kenar et al., 2014) . Furthermore, we found that about 6% of humans with autism spectrum disorder are haploid at STX1A (Kofuji et al., 2017) . Interestingly, both Stx1a À/À and Stx1a +/À mice show disruption of monoaminergic systems, which may cause the unusual behavioural profiles that are similar to neuropsychological alterations that are observed in psychiatric patients such as those with autism spectrum disorder (Fujiwara et al., 2010) . These observations suggest that STX1A is related to human neuropsychological disorders through regulation of monoamine release. STX1B may be related to human neurological disorders, such as astatic epilepsy (Schubert et al., 2014) , but the relationship between neuropsychological disorders and STX1B is not clear. DAergic neurons in the ventral tegmental area (VTA) project to the ventral striatum and receive recurrent GABAergic input (Creed et al., 2014) . Because Stx1b À/À mice show impaired GABAergic transmission, Stx1b may contribute to the regulation of DA release in the ventral striatum through GABAergic transmission. However, whether STX1B regulates DA release itself in the ventral striatum similar to STX1A is not clear.
In our current study, we examined whether STX1B contributes to the monoaminergic system and if a reduced level of STX1B induces neuropsychological alterations, similar to STX1A. However, Stx1b
À/À mice are lethal at an early postnatal age, making in vivo analysis of monoamine release in Stx1b À/À mice difficult.
Our previous study showed that the amount of Stx1a protein in Stx1a +/À mice is reduced by about 50% compared with the wild type (WT) and that Stx1a +/À mice exhibit reduced monoaminergic transmission as seen in Stx1a À/À mice (Fujiwara et al., 2010) .
In Stx1b heterozygous mutant (Stx1b +/À ) mice, the amount of Stx1b protein is reduced by about 50% without affecting the expression of other STX family members . Therefore, to clarify the contribution of Stx1b to monoaminergic transmission, monoamine release in vitro and in vivo was analysed using Stx1b +/À mice. We also analysed whether Stx1b +/À mice exhibited neuropsychological alterations.
Materials and methods

Mice
Stx1b
+/À mice were generated as reported previously and backcrossed onto the C57Bl/6J background for nine generations. Stx1b +/À and WT littermate mice were obtained by Stx1b
intercrossing. The mice were housed on a 12-h light/dark cycle, and food and water were available ad libitum. For all in vivo experiments, 12-to 15-week-old male mice were used, and the experiments were conducted during the light phase (08:00-17:00). All experimental procedures were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals approved by the Kyorin University Animal Care Committee.
Monoamine or GABA release from synaptosomes
Four mice of each genotype were used to prepare synaptosomes (SYP) for an experiment. Brain tissues were obtained from 12-to 15-week-old male mice that were deeply anesthetized by an intraperitoneal administration of 60 mg/kg pentobarbital. The midbrain including the ventral striatum and VTA was dissected from the brain, and SYP were prepared as previously described (Fujiwara et al., 2010 (Paxinos & Franklin, 1997) and fixed to the skull with dental cement. Thereafter, 0.3 mg/kg Antisedan (Orion Pharma) was injected into the mice to allow recovery from the anaesthesia. After the surgery, each mouse was allowed to recover individually in their home cage for at least 7 days before each experiment. For the study of the extracellular DA concentration in the ventral striatum ( Fig. 1D and E), a dialysis probe (membrane length 1 mm; EICOM, Kyoto, Japan) was inserted into the guide cannula, and Ringer's solution was perfused at a constant flow rate of 2 lL/min. The dialysates were collected (15 min/fraction) and subjected to high-performance liquid chromatography (HPLC) including a reversed-phase column (Eicompak CAX; EICOM), and DA was separated and detected electrochemically. The mobile phase was 0.1 M ammonium acetate buffer (pH 6.0) containing 50 mM Na 2 SO 4 , 0.1 mM EDTA and 30% methanol. The detector potential was set at 0.45 V vs. the Ag/AgCl electrode. To quantify the basal extracellular DA concentration in the ventral striatum ( Fig. 1D , WT; n = 6, Stx1b +/À ; n = 5), no net flux in vivo microdialysis was carried out as reported (Mishima et al., 2012) . In brief, after perfusion of Ringer's solution for 3 h, four concentrations (C in ; 0, 0.5, 1, 5 nM) of DA in Ringer's solution were perfused through the dialysis probe in a random order. After perfusion of each solution for 60 min, each dialysate was collected. DA concentrations in each dialysate were measured as C out . A linear equation was constructed by plotting the net flux of monoamines through the dialysis probe (C in À C out ) against C in . The extracellular DA concentrations were calculated as the concentration in the perfusion fluid at which no net flux of DA through the probe occurred (C in = C out ). For the study of the effect of GBR12909 (a DA reuptake inhibitor; Sigma-Aldrich, St. Louis, MO), conventional in vivo microdialysis was carried out as a different experiment ( Fig. 1E , WT; n = 8, Stx1b
+/À ; n = 6). In brief, after perfusion of Ringer's solution for 3 h, Ringer's solution was collected for 150 min (10 fractions). The average of the 10 consecutive fractions was defined as the basal level of the extracellular DA concentration in each mouse. Thereafter, the perfusion solution was changed to 10 lM GBR12909 for 60 min. The concentration of DA in the dialysate was calculated as a percentage of the basal level in each individual mouse. For the study of the extracellular GABA concentration in the VTA (WT; n = 5, Stx1b +/À ; n = 5), a dialysis probe was inserted into the guide cannula and perfused with Ringer's solution at a constant flow rate of 1 lL/min. After perfusion for 3 h, dialysates were collected (60 min/fraction) for 120 min to measure the basal extracellular GABA concentration. Thereafter, the perfusion solution was changed to 100 lM nipecotic acid (a GABA uptake inhibitor) in Ringer's solution, and dialysates were collected for 120 min. Each dialysate sample was mixed with o-phthaldialdehyde and subjected to HPLC including a reversed-phase column (Eicompak SC; EICOM). GABA was separated and detected electrochemically. The mobile phase was 50 mM sodium phosphate buffer (pH 6.0) containing 0.1 mM EDTA and 30% methanol. The detector potential was set at 0.6 V vs. the Ag/AgCl electrode. After each in vivo microdialysis study, mice were killed under deeply anesthetized by an intraperitoneal administration of 60 mg/kg pentobarbital, and each mouse brain was fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) by cardiac perfusion. And the brains were transferred to 30% sucrose in PBS. The serial coronal sections (30 lm) were prepared for each mouse brain, and the sections were mounted silane-coated slides. These sections were used to determine the placement site of the dialysis probe (Fig. S1 ).
GABA release from cultured neurons
In this experiment, 10 of WT neonatal mice and nine of Stx1b +/À neonatal mice were used. Hippocampal neurons were prepared as previously described . In brief, both of WT and Stx1b +/À neonatal mice were decapitated, and their brains were quickly removed into ice-cold PBS. The hippocampus was obtained from the brains and dissociated with trypsin. Dissociated cells, which included GABAergic neurons, were cultured in 24-well plates (5 9 10 4 cells/cm 2 ). After culturing for 14 days, the neurons were used for the GABA release study. The culture medium was washed out, and the medium was replaced with 100 nM [3H] GABA in assay buffer for 30 min (Bianchi et al., 2007) . After washing out the medium, the neurons were incubated with assay buffer for 30 min (basal release). After collecting the medium, the neurons were stimulated with high K solution for 5 min. After stimulation, Fig. 1 . DAergic activity in the ventral striatum of Stx1b +/À mice was enhanced, but monoamine release in vitro was not altered.
[3H] monoamine-labelled SYP were incubated with assay buffer (basal). After collecting the medium, the SYP were stimulated with high K solution (High K). The radioactivity of released and remaining [3H] monoamine contents was measured, and the release was calculated as a per cent of the total content in SYP (the sum of the released and remaining). : n = 5; *P < 0.05). (E) Ringer's solution was perfused through the dialysis probe, and dialysates were collected (15 min/fraction). After collecting 10 fractions, 10 lM GBR12909 in Ringer's solution was perfused. The data are the per cent of basal levels of DA concentrations, which were the average of 10 consecutive fractions obtained from perfusion of Ringer's solution. The extracellular DA concentration was gradually elevated after perfusion of GBR12909. The elevation in the DA concentration was higher in Stx1b +/À compared with WT mice (WT: n = 8, Stx1b
the medium was collected, and the neurons were lysed with 1% SDS to measure [3H] GABA remaining in the neurons. All fractions were mixed with Insta-Gel Plus, and radioactivity was counted by liquid scintillation counter. The amount of GABA released was calculated as a percentage of the total content (released and remaining GABA).
Pre-pulse inhibition (PPI) test
Eleven mice of each genotype were used for the PPI test, which was performed using SR-LAB (San Diego Instruments, San Diego, CA) as described previously (Fujiwara et al., 2010) . In brief, after a 5-min acclimation period in the test chamber, mice were exposed to acoustic stimuli (a 120-dB pulse for 40 ms alone or a pulse preceded by a pre-pulse of 77 dB for 20 ms; the interval between the end of the pre-pulse and the start of the startle pulse was 40 ms) under constant 65-dB background noise. These stimuli were presented eight times in random order with variable inter-trial intervals of 10-20 s. Startle responses to acoustic stimuli were measured with a piezoelectric sensor mounted under the test chamber. The PPI score in each mouse was calculated as the percentage of the reduction in the startle response to the acoustic pulse with the pre-pulse compared to the response to the acoustic pulse alone. For the pharmacological study, all drugs were purchased from Sigma-Aldrich. Haloperidol (a D 2 /D 3 receptor antagonist), eticlopride (a D 2 /D 3 receptor antagonist) or SCH39166 (a D 1 receptor antagonist) was used at a dose of 0.3 mg/kg; GBR12909 was used at a dose of 5 mg/kg; pergolide (a DA receptor agonist) was used at a dose of 10 mg/kg. All drugs were dissolved in saline immediately prior to use and administered to each mouse via intraperitoneal injection 30 min prior to the PPI test. In this test, each mouse was given drug once. The number of animals was as follows: saline, WT; n = 12, Stx1b +/À ; n = 13, haloperidol, Stx1b
; n = 13, eticlopride, Stx1b +/À ; n = 9, SCH39166, Stx1b +/À ; n = 12, Saline, WT; n = 12, Stx1b +/À ; n = 12, pergolide, WT; n = 11, Stx1b +/À ; n = 14.
Statistics
Statistical analyses were performed with GraphPad Prism (version 7.3; San Diego, CA). Data from monoamine and GABA release studies in vitro were analysed with two-way ANOVA, followed by a post hoc Bonferroni test. The data from monoamine and GABA uptake in vitro, in vivo microdialysis study and PPI test were analysed with two-tailed Student's t-tests with Welch's correction. Data from the pharmacological study in PPI were analysed with one-way ANOVA, followed by a post hoc Bonferroni test. The level of significance was set at P < 0.05.
Results
Monoamine release in vitro was normal in Stx1b +/À mice, but basal DA release in vivo was increased First, we studied monoamine release in vitro using SYP. Although monoamine release from SYP induced by high K is reduced in Stx1a À/À or Stx1a +/À mice (Mishima et al., 2012) , release was not different between WT and Stx1b +/À mice (Fig. 1A -C, DA; F 1,22 = 0.01, P = 0.97, NE; F 1,22 = 0.5, P = 0.83, 5-HT; F 1,22 = 0.3, P = 0.59). ; 117.6 AE 11.6 pmol/100 lg SYP/30 min, t = 1.56, P = 0.15). We further studied monoamine release in Stx1b +/À mouse brain with in vivo microdialysis. In this study, we analysed the elevation in the extracellular concentration of monoamines in the ventral striatum following high K stimulation (Fig. S2) . However, unlike Stx1a À/À or Stx1a +/À (Mishima et al., 2012) , the elevation in monoamine concentrations following high K stimulation was not different between WT and Stx1b +/À mice. Interestingly, the DA concentration in the basal condition was higher in Stx1b +/À compared with WT mice, although the 5-HT and NE concentrations in the basal condition were not different (Fig. S2D-F , DA, t = 3.11, P = 0.032, 5-HT, t = 0.39, P = 0.71, NE, t = 0.031, P = 0.98). Then, to quantify the basal extracellular DA concentration in the ventral striatum of Stx1b +/À mice in detail, no net flux in vivo microdialysis was carried out. As shown in Fig. 1D , in WT mice, the extracellular DA concentration in the basal condition was 3.57 AE 0.44 nM, which was almost the same as in previous reports (Chefer et al., 2006; Franklin et al., 2009) . However, in Stx1b +/À mice, the extracellular DA concentration in the ventral striatum was significantly higher than in WT mice (5.56 AE 0.6 nM, t = 4.50, P = 0.007). We further studied the effect of GBR12909, a DA transporter blocker, with conventional in vivo microdialysis (Fig. 1E ). GBR12909 suppresses DA reuptake without enhancing reverse transport by DA transporters (Eshleman et al., 1994) . Therefore, elevation of the extracellular DA concentration after perfusion of GBR12909 indicates the level of basal DA release. As shown in Fig. 1E , the extracellular DA concentration gradually increased in WT mice after perfusion of GBR12909 as previously reported (Rahman & McBride, 2000) . Sixty minutes after GBR12909 perfusion, the DA concentration in WT mice was elevated to 201.8 AE 20.1% of the basal level, which was the average of fractions 1-10. However, in Stx1b +/À mice, the DA concentration was elevated to 475.8 AE 61.3% of the basal level, which was significantly higher compared with WT mice (t = 4.25, P = 0.009). These results suggested that the basal DA release was increased in the ventral striatum of Stx1b +/À mice.
GABA release was suppressed in Stx1b +/À mice
Because in vitro DA release by high K stimulation was not altered in SYP derived from Stx1b +/À mice, we hypothesized that the higher extracellular DA concentration in the ventral striatum may have been the result of a secondary effect of perturbation of regulation of the neural system of DA secretion in the CNS. DAergic neurons in ventral striatum project to ventral striatum and the secretion of DA were regulated by GABAergic transmission in VTA (Yetnikoff et al., 2014) . Therefore, to study whether GABAergic transmission was suppressed in the VTA of Stx1b +/À mice, we used in vivo microdialysis and measured the extracellular GABA concentration in the VTA. As shown in Fig. 2A , the basal extracellular GABA concentration in the VTA was significantly decreased in Stx1b +/À compared with WT mice (t = 4.17, P = 0.003). We further studied the extracellular GABA concentration after perfusion of nipecotic acid, a GABA uptake inhibitor. As shown in Fig. 2B , the extracellular GABA concentration after perfusion of nipecotic acid was also significantly decreased in Stx1b +/À compared with WT mice (t = 3.07, P = 0.034). In WT mice, the GABA concentration was elevated to 202.3 AE 22.7% of the basal level. The elevation in the GABA concentration in Stx1b +/À mice (125.4 AE 30.7% of basal level) was significantly lower (t = 2.85, P = 0.026). These results suggested that GABAergic transmission in the VTA was suppressed in Stx1b +/À mice. We next studied if GABA release in vitro was suppressed in Stx1b +/À SYP. As shown in Fig. 3A , GABA release from SYP following high K stimulation was reduced in Stx1b +/À compared with WT mice (F 1,20 = 21.21, high K: P = 0.0002). The uptake of [3H] GABA was not different between WT and Stx1b +/À SYP (WT; 160.6 AE 10.6 pmol/100 lg SYP/30 min, Stx1b
+/À ; 178.7 AE 7.1 pmol/100 lg SYP/30 min, t = 1.42, P = 0.20). We also analysed GABA release in vitro using cultured hippocampal neurons. As shown in Fig. 3B , both the basal condition and high K resulted in reduced GABA release from cultured hippocampal neurons from Stx1b +/À compared with WT mice (F 1,42 = 18.77, basal: P = 0.038, high K: P < 0.0001). The uptake of [3H] GABA was not different between WT and Stx1b +/À neurons (WT; 13.3 AE 1.7 pmol/2 9 10 5 cells/30 min, Stx1b +/À ; 13.5 AE 0.8 pmol/ 2 9 10 5 cells/30 min, t = 0.29, P = 0.78). These results suggested that GABA release was suppressed in Stx1b +/À mice.
Disruption in the regulation of the DAergic system in Stx1b
Several studies have demonstrated that a disruption in the DAergic system in the CNS is related to altered PPI (Ralph & Caine, 2005; Duncan et al., 2006; Moy et al., 2006) , which is a well-known type of behavioural assessment of the sensory gating system. The reduction in PPI is thought to be closely related to human schizotypal abnormalities (Kilts, 2001; van den Buuse, 2010) . Because the ventral striatum is thought to be a main area of the brain that regulates PPI (Reijmers et al., 1995) , and an increase in basal DA release in the ventral striatum of Stx1b +/À mice was observed with in vivo microdialysis ( Fig. 1D and E) , we analysed whether PPI was affected in Stx1b +/À mice. As shown in Fig. 4A , PPI in Stx1b +/À mice was significantly reduced compared with WT mice (t = 4.72, P = 0.0006). We further examined if the reduction in PPI in Stx1b +/À mice was related to enhanced DAergic activity using pharmacological experiments. Interestingly, administration of haloperidol or eticlopride, which are D 2 / 3 receptor antagonists, or SCH39166, which is a D 1 receptor antagonist, rescued the suppression of PPI in Stx1b +/À mice (Fig. 4B, F 3 ,48 = 8.60, haloperidol; P = 0.001, eticlopride; P = 0.001, SCH39166; P = 0.004). Administration of these drugs did not affect PPI in WT mice (Fig. S3) . We also studied the effect of pergolide, a DA receptor agonist, in PPI (Fig. 4C) . In WT mice, PPI was disrupted by pergolide, as previously reported (Ralph-Williams et al., 2003) . However, PPI in Stx1b +/À mice did not change following administration of pergolide (F 1,45 = 6.84, P = 0.012; WT, P = 0.031; Stx1b +/À , P = 0.17). These results suggested that activation of DA receptors may be enhanced in resting conditions in Stx1b +/À mice, causing a reduction in PPI. Fig. 2 . Suppression of the GABAergic system in Stx1b +/À mice. In vivo microdialysis study of GABA in the VTA. Ringer's solution was perfused through the dialysis probe. After perfusion for 3 h, the dialysates were collected (60 min/fraction) for 120 min to measure the basal concentration. Then, the perfusion solution was changed to 100 lM nipecotic acid (a GABA uptake inhibitor) in Ringer's solution. : n = 5; *P < 0.05). 
Discussion
In this study, we found that the basal DA release in vivo was increased in the ventral striatum of Stx1b +/À mice ( Fig. 1D and E ), but monoamine release in vitro was not different between WT mice and Stx1b +/À mice ( Fig. 1A-C) . Increased DAergic activity in the ventral striatum of Stx1b +/À mice may be caused by reduced GABAergic transmission, because DA release in the ventral striatum is controlled by GABA recurrent circuits (Creed et al., 2014) , and impaired GABAergic synaptic transmission in cultured neurons was observed in Stx1b +/À mice in an electrophysiological study . As shown in Fig. 2 , in vivo microdialysis studies revealed that GABA release in the VTA was significantly decreased in Stx1b +/À compared with WT mice. We also showed that GABA release in vitro was suppressed in Stx1b +/À mice using SYP and cultured neurons (Fig. 3) . These results suggested that the reduced GABA release in the VTA enhanced DAergic activity in the ventral striatum of Stx1b +/À mice. However, GABAergic neurons in the brain are structurally and functionally diverse (Monyer & Markram, 2004) . To clarify the disruption in GABAergic transmission in the VTA, more detailed in vitro studies will be needed.
The secretion of monoamines is mediated by exocytosis of dense core vesicles, and the secretion of glutamate or GABA is mediated by exocytosis of small clear synaptic vesicles (Gondr e-Lewis et al., 2012). Our current study suggested that STX1B mainly regulate exocytosis of small clear synaptic vesicles, unlike STX1A. Because the exocytosis of small clear synaptic vesicles and dense core vesicles has different release profiles such as speeds and latencies of Ca 2+ -triggered vesicle fusion (Rettig & Neher, 2002; Martin, 2003) , STX1A and STX1B may contribute to the different release profiles.
The PPI test is a well-known behavioural test for measuring sensorimotor gating (Kilts, 2001) , and decreased PPI is considered to be a prominent endophenotype in human neuropsychological disorders such as schizophrenia . Therefore, the PPI test is thought to be a useful behavioural assessment for evaluating animal models with putative neuropsychological deficits related to human schizotypal abnormalities . Compounds that facilitate the DAergic system, such as amphetamine, disrupt PPI in mice and D 2 / 3 receptor antagonists, such as haloperidol or eticlopride , or D 1 receptor antagonists, such as SCH39166 (Ralph & Caine, 2005) , prevent the decrease in PPI in mice. Therefore, dysfunction of the DAergic system in the CNS is thought to be closely related to neuropsychological disorders such as schizophrenia. In this report, we showed that Stx1b +/À mice exhibited a reduction in PPI (Fig. 4A) , which was rescued by haloperidol, eticlopride or SCH39166 (Fig. 4B) . We also showed that administration of pergolide, a DA receptor agonist that suppressed PPI in WT mice, did not affect PPI in Stx1b +/À mice (Fig. 4C) . These results suggested that increased DAergic activity may cause schizotypal behavioural properties in Stx1b +/À mice. As described above, the increased DAergic activity in Stx1b +/À mice may be due to suppression of GABA release. Therefore, suppression of the GABAergic system may underlie the neuropsychological abnormalities in Stx1b +/À mice. In fact, previous studies suggested that impaired GABAergic transmission could : n = 11; *P < 0.05). (B), (C) For the pharmacological study, each drug was intraperitoneally administered 30 min before the PPI test. The reduction in PPI in Stx1b +/À mice was rescued by administration of haloperidol (Hal), eticlopride (Etic) or SCH39166 (SCH) (WT: n = 9, Stx1b +/À also be related to schizotypal neuropsychological abnormalities in humans via disruption of the DAergic system (Wassef et al., 2003; Yee et al., 2005) .
In addition to a reduction in PPI, anxiety-like behaviour is also a common psychiatric symptom in patients with schizophrenia (Tandon et al., 2009) . Interestingly, Stx1b +/À mice showed anxietylike behaviour in the open-field test and in the social interaction test (Fig. S4) . We do not know whether these behavioural alterations were caused by an impaired DAergic system or if other factors are involved. Brain-derived neurotrophic factor (BDNF) plays an important role in the development of GABAergic neurons (Yamada et al., 2002; Hong et al., 2008) , and impaired BDNF signalling is associated with schizotypal neuropsychological abnormalities (Angelucci et al., 2005; Gratac os et al., 2007) . Interestingly, secretion of BDNF is suppressed in Stx1b +/À mice . Reduction of BDNF release may cause schizotypal behaviour in Stx1b +/À mice. However, more detailed analysis will be needed to clarify this possibility. Considering these results, Stx1b
+/À mice are thought as a novel animal model of neuropsychological disorders such as schizophrenia.
In conclusion, reciprocal interactions between the DAergic and GABAergic neuronal systems are disrupted in Stx1b +/À mice, leading to behavioural abnormalities represented by a reduction in PPI.
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